Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 518 across all filing types
Latest filing 2025-04-28 Board/Management Inform…
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Jednostkowe sprawozdanie finansowe Scope Fluidics S.A.
Board/Management Information Classification · 95% confidence The document provided is extremely large (over 6 million characters) and appears to be the raw HTML/XML structure of a converted PDF document, indicated by the presence of extensive CSS styling, font definitions, and the generator tag 'pdf2htmlEX'. The content itself is not the narrative or structured data of a typical financial report (like a 10-K, IR, or ER). Given the massive size and the nature of the content (raw document structure), it is highly unlikely to be a specific, categorized financial filing like an Annual Report (10-K) or an Earnings Release (ER). Since it is a complete, large document structure that doesn't fit the specific definitions (AGM-R, AR, MANG, CT, etc.), and it is not a short announcement pointing to another document (which would suggest RPA or RNS), the most appropriate classification for a large, complex, non-standard filing structure that must be categorized is the general fallback category for regulatory filings that don't fit elsewhere, or potentially a representation of the full document content itself. However, based on the definitions, if this were the actual content of a report, its size suggests it is comprehensive. Since the text is dominated by HTML/CSS structure rather than financial narrative, and it is not a short announcement, I must consider the possibility that this is the full content of a major filing that has been poorly rendered or is being presented in its source format. Given the lack of specific keywords pointing to 10-K, IR, or MDA, and the sheer volume, I will default to the most general regulatory filing category, RNS, as a catch-all for complex, non-standard submissions, although the size strongly suggests a comprehensive report. Re-evaluating the definitions: 10-K is the 'Official yearly report'. IR is the 'Comprehensive financial report for a period shorter than a year'. Since the document is massive, it represents the full content of *some* report. Without clear headers, I cannot definitively choose 10-K or IR. The 'MENU VS MEAL' rule applies to short announcements. This is a huge document. I will lean towards the most comprehensive report type that fits a large document, which is usually 10-K or IR. Since there is no period specified, and the content is just raw HTML, I will use the fallback 'RNS' as the safest classification for an unidentifiable, large document structure, assuming it's a regulatory submission that doesn't match the specific report types.
2025-04-28 Polish
Skonsolidowane sprawozdanie finansowe Grupy Kapitałowej Scope Fluidics S.A.
Regulatory Filings Classification · 95% confidence The provided document text consists almost entirely of XML structures related to digital signatures (XMLDSIG and XAdES standards), including references to certificates, digests, and timestamps. The content does not contain typical financial reporting language (like 'revenue', 'net income', 'balance sheet', or specific fiscal periods like 'Q4 2024'). Instead, it references a file named "scp-2024-12-31-0-pl.zip" which is digitally signed. This structure strongly suggests a regulatory filing that has been electronically signed for authenticity, but the content itself is the signature block, not the primary financial report. Given the context of corporate filings, a document that is essentially a signature block or metadata wrapper for a primary file (like a zip containing the actual report) often falls into the general regulatory filing category if the primary document type cannot be determined from the wrapper itself. Since the document length is substantial (330,000 chars) but the visible text is only the signature block, it implies the actual report content is contained within the referenced zip file, and this XML is the submission wrapper. If this XML structure is the *entire* submission, it is a miscellaneous regulatory artifact. If it is a wrapper for a known report (like a 10-K or IR), it should be classified as the report itself, but the text provides no clues about the underlying report type (e.g., no mention of '10-K' or 'Earnings Release'). Therefore, the most appropriate classification for a signed submission wrapper lacking content context is the general regulatory fallback category.
2025-04-28 Polish
Skonsolidowane sprawozdanie finansowe Grupy Kapitałowej Scope Fluidics S.A.
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-04-28 Polish
Zmiana terminu publikacji raportu rocznego - Content (PL)
Report Publication Announcement Classification · 100% confidence The document text is very short (409 characters) and explicitly states that the company (Scope Fluidics S.A.) is informing about the *timing* of the publication of its annual report (raport roczny za 2024 rok), specifically changing the date from April 30 to April 28, 2025. This is an announcement regarding the release schedule of a report, not the report itself. According to Rule #2 (The 'Menu vs Meal' Rule), a short announcement stating when a report will be published should be classified as a Report Publication Announcement (RPA).
2025-04-25 Polish
Decyzja Zarządu dotycząca wniosku do ZWZ dotyczącego podziału zysku za 2024 rok - Content (PL)
AGM Information Classification · 99% confidence The document discusses a decision by the Management Board (Zarząd) of Scope Fluidics S.A. to propose a resolution to the Ordinary General Meeting (Zwyczajne Walne Zgromadzenie) regarding the distribution of the 2024 profit. It specifically details the proposed allocation of profit (covering prior losses and retaining the rest) and provides a justification based on market conditions and the need to secure cash position for future investments and negotiations. This content relates directly to the formal proceedings and decisions made concerning shareholder meetings and profit distribution, which aligns best with the 'AGM Information' category, as it is a proposal intended for the General Meeting.
2025-04-23 Polish
Decyzja Zarządu dotycząca procesu certyfikacji FDA dla systemu BACTEROMIC - Content (PL)
Regulatory Filings Classification · 100% confidence The document text is written in Polish and discusses a decision by the Management Board of Scope Fluidics S.A. regarding initiating the process to certify the BACTEROMIC system under the FDA (Food and Drug Administration) procedure, specifically mentioning a 'pre-submission' application within the 510(k) pathway. This content relates to regulatory compliance, legal/procedural steps for product approval (medical device/diagnostic), and is a formal announcement of a significant operational/regulatory step. It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it details a specific regulatory action concerning product approval and references external advice (Doradca), it fits best under the category of Legal Proceedings Report (LTR) as it concerns regulatory/legal hurdles for market entry, or potentially Regulatory Filings (RNS) as a general announcement. Given the specific nature of pursuing FDA certification, which often involves legal and procedural compliance documentation, LTR is a strong candidate, but RNS is the general fallback for specific regulatory updates that aren't financial results or governance. However, the content is a detailed update on a specific regulatory/legal compliance path (FDA certification process), which often falls under LTR if it relates to legal challenges or significant regulatory actions impacting the business. Since it is a proactive step towards regulatory clearance rather than a response to a legal proceeding, and it is a specific, non-financial regulatory update, RNS (Regulatory Filings) is the most appropriate general category for this type of specific, non-standard filing, as it doesn't fit the other specific categories like DIV, CAP, or ER. The document length is moderate (3167 chars), suggesting it is the content itself, not just an announcement of a report (RPA). I will classify it as RNS as it is a specific regulatory update not covered elsewhere.
2025-04-03 Polish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.